Corrigendum to "Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer": [ESMO Open 3 (2018) e000375].

ABSTRACT:

SUBMITTER: Fumet JD 

PROVIDER: S-EPMC10006516 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature